High rates of durable response are achieved with imatinib after treatment with interferon plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

Abstract

This is the largest analysis to date describing the efficacy of imatinib in patients who have received prior therapies for chronic myeloid leukemia and it demonstrates excellent responses to this treatment. (ClinicalTrials.gov identifier: NCT00006343).